Stock Financial Ratios, Dividends, Split History

AHC / A.H. Belo Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)111.87
Enterprise Value ($M)54.21
Book Value ($M)92.12
Book Value / Share4.79
Price / Book1.15
NCAV ($M)32.19
NCAV / Share1.67
Price / NCAV2.81
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 21,723,002
Common Shares Outstanding 19,299,823
Common Shares Outstanding2 2,469,635
Weighted Average Number Of Shares Outstanding Basic 21,721,497
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.10
Return on Assets (ROA)0.05
Return on Equity (ROE)0.12
Balance Sheet (mrq) ($M)
Quick Ratio2.75
Current Ratio2.88
Income Statement (mra) ($M)
Advertising Revenue143,247,000.00
Other Sales Revenue Net28,495,000.00
Subscription Revenue76,884,000.00
Sales Revenue Services Net248,626,000.00
Operating Income-10.05
Net Income10.16
Earnings Per Share Basic And Diluted0.46
Cash Flow Statement (mra) ($M)
Cash From Operations-12.10
Cash from Investing9.28
Cash from Financing9.28
Identifiers and Descriptors
Central Index Key (CIK)1413898

Split History

Stock splits are used by A.H. Belo Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

A.H. Belo: The Yield Is Not Worth The Risk

2018-06-19 seekingalpha
In this article, I will take a closer look at the fundamentals of A.H. Belo to explain why I don't think the yield is currently worth the risk. (6-0)

20 High Dividend Stocks With Too Much Cash to Count | InvestorPlace

2018-05-18 investorplace
Income investors generally look for high-dividend stocks and low risk. But that’s a difficult combination to find. Dividend yields can rise if the dividend increases; they more often, and more quickly, rise if the stock price falls. And that, in turn, means that many high-yield stocks aren’t performing all that well at the moment — and may have reasonably significant risks going forward. (351-3)

10 ‘Toxic’ Stocks Investors Will Dump Next

2018-05-04 investorplace
Warren Buffett famously said, “You only find out who is swimming naked when the tide goes out.” And in an increasingly volatile broad market, weaker stocks to sell have begun to struggle. (732-9)

A Concerning Quarter Undercuts The Bull Case For A.H. Belo

2018-05-03 seekingalpha
AHC has been a classic small-cap value play, with cash and real estate creating potential upside on an SOTP basis. (6-0)

A. H. Belo's (AHC) CEO Jim Moroney on Q1 2018 Results - Earnings Call Transcript

2018-05-03 seekingalpha
A. H. Belo Corporation (NYSE:AHC) Q1 2018 Results Conference Call May 2, 2018 10:00 AM ET (6-0)

CUSIP: 001282102